Pharmacokinetic (PK) and pharmacodynamic analyses of once-and twice-daily darunavir/ ritonavir (DRV/r) 
Methods
Sparse blood sampling for PK evaluations was taken at Weeks 4, 8, 24 and 48 to determine DRV trough concentrations (C 0h ) and exposure (AUC 24h , calculated as AUC 12h x 2 for bid) using a population pharmacokinetic model. Relationships between PK parameters and efficacy (change in log 10 HIV-1 RNA and virological response [HIV-1 RNA <50 copies/mL]) were assessed using ANCOVAs. Relationships between PK parameters and occurrence of adverse events of interest and laboratory lipid abnormalities were evaluated using descriptive statistics.
Results
PK data were available for 280 DRV/r qd patients and 278 bid patients. Median (range) C 0h was 1896 (184-7881) ng/mL for DRV/r qd and 3197 (250-11,865) ng/mL for DRV/r bid. Median (range) AUC 24h for DRV/r qd was 87,788 (45,456-236,920) ng.h/mL and 109,401 (48,934-323,820) ng.h/mL for bid. No relevant relationships were observed between DRV PK and efficacy: changes from baseline in HIV-1 RNA log 10 copies/mL at Week 48 for pooled data by DRV AUC 24h quartile ranges (≤79,576; 79,577-100,376; 100,377-119,356 ; >119,356 ng.h/mL) were -2.06, -2.22, -2.19, and -2.08 log 10 copies/mL, respectively. The % patients achieving HIV-1 RNA <50 copies/mL by these quartile ranges were 82.0%, 88.5%, 82.6% and 76.5% (observed data), respectively. In a logistic regression analysis adjusting for baseline viral load, AAG levels and number of sensitive NRTIs in the optimised background regimen, there were no relevant relationships between PK and virological response. No apparent relationships were observed between DRV PK and occurrence of rash-, cardiac-, GI-, liver-, lipid-and glucose-related AEs or laboratory lipid abnormalities.
Conclusions
Dosing with DRV/r 800/100mg qd resulted in lower C 0h and AUC 24h compared to DRV/r 600/100mg bid; however, comparable efficacy between DRV/r qd and bid confirmed adequate DRV concentrations were achieved following qd dosing. No relevant relationships were observed between DRV PK and efficacy or safety at Week 48.
